Literature DB >> 29743720

Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.

Ying Guo1,2, Hui Yang1,2, Shi Chen1,2, Peng Zhang1,2, Rong Li1,2, Stephen D Nimer1,2, J William Harbour1,2,3,4, Mingjiang Xu5,6, Feng-Chun Yang7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29743720      PMCID： PMC6168429          DOI： 10.1038/s41375-018-0126-9

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB.

Authors:  Johanna C Scheuermann; Andrés Gaytán de Ayala Alonso; Katarzyna Oktaba; Nga Ly-Hartig; Robert K McGinty; Sven Fraterman; Matthias Wilm; Tom W Muir; Jürg Müller
Journal:  Nature       Date:  2010-05-02       Impact factor: 49.962

2.  The Additional sex combs gene of Drosophila is required for activation and repression of homeotic loci, and interacts specifically with Polycomb and super sex combs.

Authors:  T A Milne; D A Sinclair; H W Brock
Journal:  Mol Gen Genet       Date:  1999-06

3.  Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.

Authors:  Jiapeng Wang; Zhaomin Li; Yongzheng He; Feng Pan; Shi Chen; Steven Rhodes; Lihn Nguyen; Jin Yuan; Li Jiang; Xianlin Yang; Ophelia Weeks; Ziyue Liu; Jiehao Zhou; Hongyu Ni; Chen-Leng Cai; Mingjiang Xu; Feng-Chun Yang
Journal:  Blood       Date:  2013-11-19       Impact factor: 22.113

4.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

5.  Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels.

Authors:  Daichi Inoue; Masaki Matsumoto; Reina Nagase; Makoto Saika; Takeshi Fujino; Keiichi I Nakayama; Toshio Kitamura
Journal:  Exp Hematol       Date:  2015-12-15       Impact factor: 3.084

Review 6.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388

7.  Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.

Authors:  Anand Balasubramani; Antti Larjo; Jed A Bassein; Xing Chang; Ryan B Hastie; Susan M Togher; Harri Lähdesmäki; Anjana Rao
Journal:  Nat Commun       Date:  2015-06-22       Impact factor: 14.919

8.  ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis.

Authors:  Zhaomin Li; Peng Zhang; Aimin Yan; Zhengyu Guo; Yuguang Ban; Jin Li; Shi Chen; Hui Yang; Yongzheng He; Jianping Li; Ying Guo; Wen Zhang; Ehsan Hajiramezanali; Huangda An; Darlene Fajardo; J William Harbour; Yijun Ruan; Stephen D Nimer; Peng Yu; Xi Chen; Mingjiang Xu; Feng-Chun Yang
Journal:  Sci Adv       Date:  2017-01-20       Impact factor: 14.136

9.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Authors:  Omar Abdel-Wahab; Mazhar Adli; Lindsay M LaFave; Jie Gao; Todd Hricik; Alan H Shih; Suveg Pandey; Jay P Patel; Young Rock Chung; Richard Koche; Fabiana Perna; Xinyang Zhao; Jordan E Taylor; Christopher Y Park; Martin Carroll; Ari Melnick; Stephen D Nimer; Jacob D Jaffe; Iannis Aifantis; Bradley E Bernstein; Ross L Levine
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

10.  Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.

Authors:  Hui Yang; Stefan Kurtenbach; Ying Guo; Ines Lohse; Michael A Durante; Jianping Li; Zhaomin Li; Hassan Al-Ali; Lingxiao Li; Zizhen Chen; Matthew G Field; Peng Zhang; Shi Chen; Shohei Yamamoto; Zhuo Li; Yuan Zhou; Stephen D Nimer; J William Harbour; Claes Wahlestedt; Mingjiang Xu; Feng-Chun Yang
Journal:  Blood       Date:  2017-11-07       Impact factor: 25.476
View more
  10 in total

Review 1.  Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.

Authors:  Shuhei Asada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2018-12-05       Impact factor: 2.490

2.  Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.

Authors:  Lu Wang; Noah Warren Birch; Zibo Zhao; Carson Meredith Nestler; Alexander Kazmer; Anthony Shilati; Alisha Blake; Patrick Alexander Ozark; Emily Jane Rendleman; Didi Zha; Caila Ann Ryan; Marc Alard Jonathan Morgan; Ali Shilatifard
Journal:  Nat Cancer       Date:  2021-05-25

3.  circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia.

Authors:  Shweta Pradip Jadhav; Nishi Kumari; Larry Ng; Pei Fang Tan; Nicole Shu Ling Yeo-Teh; Yufen Goh; Wee Nih Fam; Jia Qi Tng; Johann Shane Tian; Bryan T H Koh; Chan Ming Chun; Wilson Wang; Wee Joo Chng; Melissa Jane Fullwood; Ernesto Guccione; Neerja Karnani; Daniel G Tenen; Sudhakar Jha
Journal:  Haematologica       Date:  2019-11-28       Impact factor: 9.941

4.  ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.

Authors:  Aileen Patricia Szczepanski; Zibo Zhao; Tori Sosnowski; Young Ah Goo; Elizabeth Thomas Bartom; Lu Wang
Journal:  Genome Med       Date:  2020-07-15       Impact factor: 11.117

5.  An Adversarial DNA N6-Methyladenine-Sensor Network Preserves Polycomb Silencing.

Authors:  Soo-Mi Kweon; Yibu Chen; Eugene Moon; Kotryna Kvederaviciutė; Saulius Klimasauskas; Douglas E Feldman
Journal:  Mol Cell       Date:  2019-04-11       Impact factor: 17.970

6.  Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development.

Authors:  Friederike Matheus; Ejona Rusha; Rizwan Rehimi; Lena Molitor; Anna Pertek; Miha Modic; Regina Feederle; Andrew Flatley; Elisabeth Kremmer; Arie Geerlof; Valentyna Rishko; Alvaro Rada-Iglesias; Micha Drukker
Journal:  Stem Cell Reports       Date:  2019-04-18       Impact factor: 7.765

Review 7.  Emerging multifaceted roles of BAP1 complexes in biological processes.

Authors:  Aileen Patricia Szczepanski; Lu Wang
Journal:  Cell Death Discov       Date:  2021-01-22

8.  Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.

Authors:  Natsumi Tsuboyama; Ru Wang; Aileen Patricia Szczepanski; Huanhuan Chen; Zibo Zhao; Lei Shi; Lu Wang
Journal:  Oncogene       Date:  2022-02-22       Impact factor: 9.867

Review 9.  ASXL1/2 mutations and myeloid malignancies.

Authors:  Edward A Medina; Caroline R Delma; Feng-Chun Yang
Journal:  J Hematol Oncol       Date:  2022-09-06       Impact factor: 23.168

10.  MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.

Authors:  Natsumi Tsuboyama; Aileen Patricia Szczepanski; Zibo Zhao; Lu Wang
Journal:  Genome Biol       Date:  2022-09-30       Impact factor: 17.906
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.